These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32572955)

  • 1. Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Roshanravan N; Shakeri-Bavil A; Asghari-Jafarabadi M; Farrin N; Mobasseri M
    J Cell Physiol; 2021 Jan; 236(1):417-426. PubMed ID: 32572955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: A randomized controlled trial.
    Tutunchi H; Zolrahim F; Nikbaf-Shandiz M; Naeini F; Ostadrahimi A; Naghshi S; Salek R; Najafipour F
    Front Pharmacol; 2023; 14():1144550. PubMed ID: 37089938
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
    Tutunchi H; Ebrahimi-Mameghani M; Hosseinzadeh-Attar MJ; Roshanravan N; Mobasseri M; Najafipour F; Naeini F; Naghshi S; Asghari S; Akbarzadeh M; Soleimanzadeh H; Ostadrahimi A
    Clin Nutr ESPEN; 2023 Dec; 58():311-319. PubMed ID: 38057021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
    Li L; Li L; Chen L; Lin X; Xu Y; Ren J; Fu J; Qiu Y
    J Pharmacol Sci; 2015 Mar; 127(3):244-50. PubMed ID: 25837920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Hosseinpour-Arjmand S; Amirkhizi F; Ebrahimi-Mameghani M
    J Clin Pharm Ther; 2019 Apr; 44(2):258-267. PubMed ID: 30585337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Maleki V
    Obes Rev; 2019 Jul; 20(7):1057-1069. PubMed ID: 31111657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oleoylethanolamide increases the expression of PPAR-Α and reduces appetite and body weight in obese people: A clinical trial.
    Laleh P; Yaser K; Abolfazl B; Shahriar A; Mohammad AJ; Nazila F; Alireza O
    Appetite; 2018 Sep; 128():44-49. PubMed ID: 29787831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial.
    Tutunchi H; Naeini F; Saghafi-Asl M; Farrin N; Monshikarimi A; Ostadrahimi A
    Health Promot Perspect; 2020; 10(4):373-382. PubMed ID: 33312933
    [No Abstract]   [Full Text] [Related]  

  • 10. Sini powder ameliorates the inflammatory response in rats with stress-induced non-alcoholic fatty liver disease by inhibiting the nuclear factor kappa-B / pyrin domain-containing protein 3 pathway.
    Mu J; Cheng F; Wang Q; Wang X; Zhu W; Ma C; Yin X; Ren B; Lian Y; Du X; Zhang H; Liu S; Zhang S
    J Tradit Chin Med; 2020 Apr; 40(2):253-266. PubMed ID: 32242391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
    Lee HA; Moon H; Kim Y; Lee HA; Kim HY
    Trials; 2023 Aug; 24(1):490. PubMed ID: 37533096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.
    Chen L; Li L; Chen J; Li L; Zheng Z; Ren J; Qiu Y
    Oncotarget; 2015 Dec; 6(40):42530-40. PubMed ID: 26729705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
    Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
    Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease.
    Tan DY; Shi HY; Li CP; Zhong XL; Kang M
    World J Gastroenterol; 2015 May; 21(19):5877-83. PubMed ID: 26019451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Barroso LN; Salarini J; Leite NC; Villela-Nogueira CA; Dávalos A; Carmo MDGT; Ferreira Peres WA
    Clin Nutr ESPEN; 2023 Oct; 57():117-125. PubMed ID: 37739645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial.
    Payahoo L; Khajebishak Y; Alivand MR; Soleimanzade H; Alipour S; Barzegari A; Ostadrahimi A
    Appetite; 2019 Oct; 141():104301. PubMed ID: 31132422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial.
    Ostadrahimi A; Khajebishak Y; Moradi F; Payahoo L
    BMC Endocr Disord; 2024 Oct; 24(1):210. PubMed ID: 39379951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
    Chen M; Xing J; Pan D; Peng X; Gao P
    Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NF-kB danger signaling in rat frontal cortex and depressive-like behavior induced by ethanol binge administration.
    Antón M; Alén F; Gómez de Heras R; Serrano A; Pavón FJ; Leza JC; García-Bueno B; Rodríguez de Fonseca F; Orio L
    Addict Biol; 2017 May; 22(3):724-741. PubMed ID: 26857094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.